ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pregabalin

Also written as “pregabalin”, “pregabalin (Lyrica)” and “Pregabalin ER”.

Its studies are mostly in Neuralgia · Fibromyalgia · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 18 companies.

Drug pagePregabalin: every studyMany companies study it; this page follows only the 142 they lead. All 390 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 31, 2005142 company-led studies, 1 open or runningNext primary completion: Jun 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris940 open or runningphase 4since Aug 31, 2005Aug 30, 2005none ahead
Pfizerits history only180 open or runningphase 4since Apr 16, 2012Aug 30, 2005none ahead
Yuhanits history only80 open or runningphase 4since Apr 13, 2021Aug 17, 2011none ahead
GL Pharm Techits history only40 open or runningphase 1since Jul 4, 2012Jul 4, 2012none ahead
Laboratorios Silanes S.A. de C.V.its history only30 open or runningphase 3since Apr 4, 2022Apr 4, 2022none ahead
Merckits history only20 open or runningphase 1since Dec 7, 2007Dec 7, 2007none ahead
Nevakarits history only20 open or runningphase 2since Jul 27, 2020Jan 29, 2020none ahead
Analgesic Solutionsits history only10 open or runningphase 4since Dec 13, 2012Dec 13, 2012none ahead
Depomedits history only10 open or runningphase 4since Jun 5, 2017Jun 5, 2017none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Sep 4, 2014Sep 4, 2014none ahead

Also a collaborator on its studies: Nevakar Injectables, Boehringer Ingelheim and Astellas Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Dec 1, 2006.

  1. Feb 16, 2011Phase 4 study in Low Back PainNCT01298466
  2. Apr 7, 2011Phase 3 study in Diabetic NeuropathiesNCT01332149 · 626 enrolled · China
  3. Jun 30, 2011Phase 3 study in FibromyalgiaNCT01387607 · 343 enrolled · China
  4. Sep 8, 2011Phase 3 study in FibromyalgiaNCT01432236 · 197 enrolled · United States, Canada, Italy and more
  5. Oct 17, 20112 phase 3 studiesNCT01463306, NCT01455415
  6. Oct 17, 2011Phase 4 study in Neuralgia, PostherpeticNCT01455428 · 223 enrolled · China
  7. Nov 15, 2011Phase 3 study in Diabetic Peripheral NeuropathyNCT01474772 · 217 enrolled · United States, Czechia, South Africa and more
  8. Oct 3, 2012Phase 3 study in NeuralgiaNCT01701362 · 542 enrolled · United States, Bulgaria, Canada and more
  9. Nov 12, 2012Phase 4 study in Breast FeedingNCT01727791 · 10 enrolled · Belgium
  10. Nov 27, 2012Phase 3 study in SeizuresNCT01747915 · 219 enrolled · United States, Austria, Belarus and more
  11. Apr 15, 2013Phase 4 study in Chronic Low Back Pain With a Neuropathic ComponentNCT01838044 · 180 enrolled · Brazil, Chile, Colombia and more
  12. Feb 25, 2014Phase 3 study in EpilepsyNCT02072824 · 175 enrolled · United States, Belarus, Belgium and more
  13. Feb 10, 2016Phase 1 study in HealthyNCT02725112 · 25 enrolled · United States
  14. Jun 9, 2019Named pregabalinINNProposed as its International Nonproprietary Name in WHO's List 121
  15. Sep 13, 2021Phase 4 study in Abuse PotentialNCT05053126 · 60 enrolled · United States

TargetBeta

“Voltage-gated calcium channel modulator”ChEMBL 37, by rule

Other programs on the same 26 targets

ProgramCompanyFurthest phaseStudies
GabapentinruleViatrisphase 449

Studies

The newest 60 of 94 Viatris leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT05053126Abuse Potential · United States4CompletedApr 1, 202260
NCT02725112Healthy · United States1CompletedMay 22, 201625
NCT02072824Epilepsy · United States, Belarus, Belgium and more3CompletedMar 13, 2018175
NCT01838044Chronic Low Back Pain With a Neuropathic Component · Brazil, Chile, Colombia and more4TerminatedMay 2015180
NCT01747915Seizures · United States, Austria, Belarus and more3CompletedFeb 20, 2019219
NCT01727791Breast Feeding · Belgium4CompletedAug 201310
NCT01701362Neuralgia · United States, Bulgaria, Canada and more3CompletedAug 2015542
NCT01474772Diabetic Peripheral Neuropathy · United States, Czechia, South Africa and more3CompletedJul 2013217
NCT01463306Epilepsy · United States, Belarus, Belgium and more3CompletedAug 22, 2019605
NCT01455428Neuralgia, Postherpetic · China4CompletedJan 2014223
NCT01455415Painful Diabetic Peripheral Neuropathy · United States, Czechia, Italy and more3CompletedNov 2013306
NCT01432236Fibromyalgia · United States, Canada, Italy and more3CompletedJul 2013197
NCT01387607Fibromyalgia · China3CompletedOct 31, 2016343
NCT01332149Diabetic Neuropathies · China3CompletedApr 2014626
NCT01298466Low Back Pain4WithdrawnFeb 20130
NCT01271933Fibromyalgia · United States, Canada, India and more3CompletedJul 2012441
NCT01270828Neuralgia, Postherpetic · United States, Bulgaria, Colombia and more3CompletedSep 2014806
NCT01262677Seizures · United States, Argentina, Bosnia and Herzegovina and more3CompletedJul 31, 2012325
NCT01257516Healthy · Belgium1CompletedMar 201118
NCT01220219Healthy · Belgium1CompletedJan 201124
NCT01202435Healthy · Belgium1CompletedNov 201018
NCT01202422Healthy · Belgium1CompletedNov 201024
NCT01202227Spinal Cord Diseases · Japan3CompletedMar 2012104
NCT01145417Neuralgia · United States, Colombia, India and more3TerminatedMay 2012217
NCT01080612Healthy · United States1CompletedJun 201024
NCT01061372Restless Legs Syndrome3WithdrawnAug 20110
NCT01057693Diabetic Neuropathies · United States, Canada, Puerto Rico and more3CompletedJan 30, 2012633
NCT01049217Pain · United States, Colombia, Dominican Republic and more3TerminatedMay 2012377
NCT01020526Fibromyalgia · United States, Czechia, India4CompletedJun 201563
NCT01020474Fibromyalgia · United States, Czechia, India and more4CompletedDec 2014107
NCT01009541Healthy · Belgium1CompletedDec 200920
NCT00991276Restless Legs Syndrome · United States3CompletedJun 201185
NCT00978341Spinal Cord Injuries · Australia–TerminatedOct 200815
NCT00905437Pain · India3TerminatedJul 201272
NCT00883740Fibromyalgia · United States, Canada, Germany3CompletedJun 2010119
NCT00830167Fibromyalgia · Japan3CompletedMay 2011498
NCT00830128Fibromyalgia · Japan3CompletedFeb 2011106
NCT00806026Idiopathic Restless Legs Syndrome · United States, Austria, Finland and more3CompletedMay 2011731
NCT00676403Restless Legs Syndrome · United States, Austria, Germany and more2CompletedJan 2009137
NCT00654940Neuralgia · Canada, Sweden1CompletedFeb 200925
NCT00645398Fibromyalgia · United States3Completed751
NCT00631943Neuralgia · India3Completed112
NCT00629681Diabetic Neuropathies · Germany4Completed217
NCT00631696Healthy · United States4CompletedFeb 2012222
NCT00624780Generalized Anxiety Disorder · Argentina, Austria, Costa Rica and more4CompletedApr 2012615
NCT00610155Pain · United Kingdom–CompletedJul 201018
NCT00596466Epilepsy · United States, Czechia, Hong Kong and more3CompletedDec 201175
NCT00553475Diabetic Neuropathies · Japan3CompletedMar 2009314
NCT00553280Diabetic Neuropathies · Japan3CompletedJan 2010123
NCT00551135Pain, Postoperative · United States, Australia, Canada and more3CompletedJun 2009425
NCT00537940Epilepsy · Costa Rica, El Salvador, Guatemala and more4CompletedJul 2013482
NCT00537238Seizures · Belgium, Bulgaria, Colombia and more3CompletedMay 2012509
NCT00524030Epilepsies, Partial · United States, Czechia, Hong Kong and more3TerminatedApr 2011161
NCT00468845Pain, Postoperative · United States, Canada, Czechia and more3CompletedMay 2010501
NCT00448916Epilepsies, Partial · United States, Korea, Republic of, Mexico3CompletedOct 201354
NCT00442546Osteoarthritis · United States3CompletedDec 2008307
NCT00437281Epilepsies, Partial · United States, Korea, Republic of, Mexico2CompletedNov 201265
NCT00424372Neuralgia, Postherpetic · Japan3CompletedAug 19, 2008126
NCT00413010Generalized Anxiety Disorder · United States, Czechia, Estonia and more3CompletedFeb 2008356
NCT00407797Seizures · Mexico4TerminatedAug 2009136

How it is read

Names in the registry

  • “Pregabalin”, 80 entries
  • “pregabalin”, 43 entries
  • “pregabalin (Lyrica)”, 7 entries
  • “Pregabalin ER”, 6 entries
  • “Pregabalin 150mg”, 5 entries

Codes read as this program: YHD1119.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.